Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New High-Dose semaglutide shows major weight loss in obesity trial

NCT ID NCT05646706

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested a high dose (7.2 mg weekly) of semaglutide, a drug already used for weight loss, in 1407 adults with obesity. Participants received the drug or a placebo, plus lifestyle advice. The main goal was to measure weight loss from start to 72 weeks. Results showed significant weight reduction with the high dose compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If successful, this high-dose semaglutide could offer a more effective weight-loss option for people with obesity, helping them achieve and maintain significant weight loss.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to everyone. Side effects like nausea or vomiting are common, and long-term safety at this high dose is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,407 people

The number who actually took part.

Started

Jan 2023

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female. * Age above or equal to 18 years at the time of signing informed consent. * Body mass index (BMI) greater than or equal to 30.0 kilogram per square meter (kg/m\^2). * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * HbA1c greater than or equal to 48 millimoles per mole (mmol/mol) (6.5 percent) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes. * Treatment with glucose-lowering agent(s) within 90 days before screening. * A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening irrespective of medical records. * Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • "Ippokrateio" G.H. of Thessaloniki

    Thessaloniki, 54642, Greece

  • "Thermi" Private Hosital

    Thessaloniki, 57001, Greece

  • AHEPA General University Hospital

    Thessaloniki, 54636, Greece

  • AIPSMC Dr. Evelina Zlatanova EOOD

    Varna, 9010, Bulgaria

  • AMC Community Endocrinology

    Albany, New York, 12203, United States

  • APDP - Associação Protectora dos Diabéticos de Portugal

    Lisbon, 1250-230, Portugal

  • Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology

    Sofia, 1407, Bulgaria

  • Amarillo Med Spec LLP

    Amarillo, Texas, 79106, United States

  • Bajcsy-Zsilinszky Kórház

    Budapest, 1106, Hungary

  • Belinus Bt.

    Debrecen, Hajdú-Bihar, 4025, Hungary

  • Borbánya Praxis E.Ü. Kft.

    Nyíregyháza, Szabolcs-Szatmar Varmegye, 4405, Hungary

  • Centrum Medyczne Pratia Gdynia

    Gdynia, Pomeranian Voivodeship, 81-338, Poland

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama, 36106, United States

  • ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.

    Budapest, 1089, Hungary

  • DCC Ascendent OOD

    Sofia, 1202, Bulgaria

  • DCOL Ctr for Clin Res

    Longview, Texas, 75605, United States

  • Deepak Lakha

    Johannesburg, Gauteng, 1820, South Africa

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Dom srdca, s.r.o.

    Žilina, 01001, Slovakia

  • Dr N.K. Gounden Medical Centre

    Durban, KwaZulu-Natal, 4093, South Africa

  • Dr T Padayachee

    eMkhomazi, KwaZulu-Natal, 4170, South Africa

  • East West Med Res Inst

    Honolulu, Hawaii, 96814, United States

  • Edumed Broumov

    Broumov, 550 01, Czechia

  • Elligo Clin Res Centre

    Austin, Texas, 78704, United States

  • Endocare

    Prague, 140 00, Czechia

  • Fakultní nemocnice Královské Vinohrady_Praha 10

    Prague, 10034, Czechia

  • Falck Norge AS

    Hamar, 2317, Norway

  • Fejér Megyei Szent György Oktatókórház

    Székesfehérvár, 8000, Hungary

  • Fledip s.r.o.

    Prague, 160 00, Czechia

  • Florida Inst For Clin Res LLC

    Orlando, Florida, 32825, United States

  • Florida Institute For Clinical Research LLC

    Orlando, Florida, 32825, United States

  • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann

    Witten, 58455, Germany

  • Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter

    Athens, 11527, Greece

  • General Hospital of Lamia

    Lamia, 35100, Greece

  • General Hospital of Thessaloniki 'G. Gennimatas

    Thessaloniki, 54635, Greece

  • Hamilton Med Res Group

    Hamilton, Ontario, L8M 1K7, Canada

  • Healthscan Clinical Trials,LLC.

    Montgomery, Alabama, 36106, United States

  • Hemant Makan

    Johannesburg, Gauteng, 1827, South Africa

  • Hospital da Luz Arrabida, S.A.

    Vila Nova de Gaia, 4400-346, Portugal

  • Hospital da Luz Lisboa, S.A.

    Lisbon, 1500-650, Portugal

  • IN-DIA s.r.o.

    Lučenec, 984 01, Slovakia

  • IPMC - Dr. Elizabeta Dimitrova

    Petrich, 2850, Bulgaria

  • Iatriko Athinon 'Palaiou Falirou'

    Athens, 17562, Greece

  • Iatriko Athinon (Athens Medical Canter)

    Athens, 15125, Greece

  • InnoDiab Forschung GmbH

    Essen, 45136, Germany

  • Institut klinické a experimentalni mediciny

    Prague, 14021, Czechia

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida, 32216, United States

  • Kresmed Sp. z o. o.

    Bialystok, Podlaskie Voivodeship, 15-481, Poland

  • Lausmed Kft.

    Baja, Bács-Kiskun county, 6500, Hungary

  • Lenmed Shifa Private Hospital

    Durban, KwaZulu-Natal, 4901, South Africa

  • MED-CENTRUM, s.r.o.

    Martin, 036 01, Slovakia

  • MED-TIMA Kft.

    Budapest, 1132, Hungary

  • MEDIMAD, s.r.o., Endokrinologicka ambulancia

    Bratislava, 842 31, Slovakia

  • MEDIVASA, s.r.o., Angiologicka ambulancia

    Žilina, 010 01, Slovakia

  • MUDr. Dagmar Prokesova, Endokrinologicka ambulancia

    Bratislava, 821 01, Slovakia

  • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET

    Krakow, Lesser Poland Voivodeship, 31-261, Poland

  • Medi-Clinic Bloemfontein

    Bloemfontein, Free State, 9301, South Africa

  • Medical Center Medical Plus EOOD

    Varna, 9000, Bulgaria

  • Medical Centre Medical Arts Medico-dental centre

    Sofia, 1618, Bulgaria

  • Medical University Of South Carolina

    Charleston, South Carolina, 29425, United States

  • Medical center Hippocrates Lukovit EOOD

    Lukovit, 5770, Bulgaria

  • Medical center Smolyan clinical research OOD

    Smolyan, 4700, Bulgaria

  • Medical centre Zdrave 1 OOD

    Kozloduy, 3320, Bulgaria

  • MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin

    Münster, 48153, Germany

  • Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR

    Berlin, 13597, Germany

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • Milestone Research

    London, Ontario, N5W 6A2, Canada

  • NBR Polska Tomasz Klodawski

    Warsaw, 00-710, Poland

  • NZOZ "CenterMed Lublin" Sp. z o.o.

    Lublin, Lublin Voivodeship, 20-044, Poland

  • NZOZ Przychodnia Specjalistyczna Medica

    Lublin, Lubelski, 20-538, Poland

  • National Clin Res Inc.

    Richmond, Virginia, 23294, United States

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Nova Scotia Hlth Halifax

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Ocean West Research Clinic

    Surrey, British Columbia, V3Z 2N6, Canada

  • Ordinace praktického lékaře

    Benátky Na Jizerou, 29471, Czechia

  • Oslo universitetssykehus HF Aker

    Oslo, 0373, Norway

  • PANSTWOWY INSTYTUT MEDYCZNY MSWiA

    Warsaw, 02-507, Poland

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina, 27408, United States

  • Phoenix Pharma

    Port Elizabeth, Eastern Cape, 6001, South Africa

  • Poliklinika Michnova - Obezitologie

    Prague, 149 00, Czechia

  • Praxis Dr. med. M. Esser

    Essen, 45219, Germany

  • Praxis Dr. med. Wenzl-Bauer

    Rehlingen-Siersburg, 66780, Germany

  • Precise Clinical Solutions (Pty) Ltd

    Durban, KwaZulu-Natal, 4092, South Africa

  • Premier Clinical Trial Research Network (PCTRN)

    Hamilton, Ontario, L8L 5G4, Canada

  • RED-Institut für medizinische Forschung und Fortbildung GmbH

    Oldenburg in Holstein, 23758, Germany

  • SGHAT Dr. Shterev EOOD

    Sofia, 1330, Bulgaria

  • SIN AZUCAR s.r.o.

    Malacky, 901 01, Slovakia

  • SVAJDLEROVA, s.r.o.

    Prešov, 080 01, Slovakia

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834, United States

  • Soweto Clinical Trial Centre

    Johannesburg, Gauteng, 1818, South Africa

  • Sugar Lakes Family Practice PA

    Sugar Land, Texas, 77479, United States

  • Sykehuset i Vestfold HF, Tønsberg

    Tønsberg, 3116, Norway

  • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano

    Senhora Da Hora, Matosinhos, Matosinhos, 4464-513, Portugal

  • ULS De São João, E.P.E. - Hospital de São João

    Porto, 4200-319, Portugal

  • UT Southwestern Medical Center-CRU

    Dallas, Texas, 75390, United States

  • Unidade Local De Saúde De Lisboa Ocidental E.P.E. - Hospital Egas Moniz

    Lisbon, 1349-019, Portugal

  • Univ of Alabama Birmingham

    Birmingham, Alabama, 35294, United States

  • University Hospital of Athens ATTIKON

    Athens, Attica, 12462, Greece

  • University of North Carolina

    Chapel Hill, North Carolina, 27514, United States

  • Uniwersyteckie Centrum Kliniczne SUM w Katowicach

    Katowice, 40-752, Poland

  • Velocity Clin Res, Dallas

    Dallas, Texas, 75230, United States

  • Wharton Med Clin Trials

    Hamilton, Ontario, L8L 5G8, Canada

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, L8L 5G8, Canada

  • Wits Bara Clinical Trial Site

    Johannesburg, Gauteng, 2013, South Africa

  • Zentrum fuer klinische Studien Suedbrandenburg GmbH

    Elsterwerda, 04910, Germany

  • Zentrum für klinische Forschung, Dr. med. Lüdemann

    Falkensee, 14612, Germany

  • Zentrum für klinische Studien Allgäu Oberschwaben

    Wangen, 88239, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.